We are live on ! Find out more
TARO

Taro Pharmaceutical Industries Ltd.

Delisted

TARO was delisted on the 21st of June, 2024.

71 hedge funds and large institutions have $186M invested in Taro Pharmaceutical Industries Ltd. in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

85% more capital invested

Capital invested by funds: $101M → $186M (+$85.2M)

64% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 14

47% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 15

15% more funds holding

Funds holding: 6271 (+9)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $800K

Holders
71
Holders Change
+9
Holders Change %
+14.52%
% of All Funds
1.11%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
23
Increased
22
Reduced
15
Closed
14
Calls
Puts
$800K
Net Calls
-$800K
Net Calls Change
-$791K

TARO Hedge Fund Activity: Q2 2023 in Review

71 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q2 2023, worth a combined $186M — up 85% from $101M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new TARO positions and 14 closed out — a net gain of 9 holders — while 22 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $13.3M. The largest seller was Hotchkis & Wiley Capital Management, cutting an estimated $1.9M.

  • 71 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q2 2023, up from 62 in Q1 2023.
  • Funds reported $186M of Taro Pharmaceutical Industries Ltd. stock for Q2 2023, up 85% quarter-over-quarter.
  • 23 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q2 2023 and 14 closed out, a net change of +9 holders.
  • The largest Taro Pharmaceutical Industries Ltd. buyer in Q2 2023 was BlackRock, an estimated $13.3M added.
  • The largest Taro Pharmaceutical Industries Ltd. seller in Q2 2023 was Hotchkis & Wiley Capital Management, an estimated $1.9M sold.

Based on aggregated 13F filings for Q2 2023.